Omthera Pharmaceuticals

About:

Omthera Pharmaceuticals develops therapies for patients with elevated triglyceride levels and increased risk of cardiovascular disease.

Website: http://www.omthera.com

Twitter/X: astrazenecaus

Top Investors: New Enterprise Associates, Sofinnova Partners

Description:

Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.

Total Funding Amount:

$60.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Princeton, New Jersey, United States

Founded Date:

2008-01-01

Founders:

Jerry Wisler, Michael Davidson

Number of Employees:

11-50

Last Funding Date:

2013-02-28

IPO Status:

Delisted

Industries:

© 2025 bioDAO.ai